Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.30 USD

73.30
7,101,316

+1.66 (2.32%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $73.43 +0.13 (0.18%) 6:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

2023 could be a year of heightened biotech dealmaking activity

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Andrew Rocco headshot

Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead

Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.

Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

Smart Beta ETF report for SPYD

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio

Ligand's (LGND) proprietary platforms enable it to form partnerships with several leading drug companies, providing it with funds through milestone and royalty payments.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.

Bristol Myers' (BMY) Breyanzi Gets Positive CHMP Opinion

Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed or refractory large B-cell lymphoma after one prior treatment.

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?

Style Box ETF report for DVY

IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?

Smart Beta ETF report for DVY

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB